報價延遲最少15分鐘:2024/12/24 12:52 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.115 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.12/-2.30
|
|
企業價值
3.61M
|
| 資產負債 |
|
每股賬面淨值
0.66
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:52 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues. |